Asymmetric [3 + 2] spiroannulation of pyrazolone-derived Morita–Baylis–Hillman carbonates with alkynyl ketones: facile access to spiro[cyclopentadiene-pyrazolone] scaffolds

Xingfu Wei, Yue Huang, Wenyao Wang, Shiqiang Wei, Jingping Qu and Baomin Wang*

State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Sciences, School of Chemical Engineering, Dalian University of Technology, Dalian 116024, People's Republic of China.

E-mail: bmwang@dlut.edu.cn

Contents:

1.	General information	·S1
2.	General procedure and characterization of MBH Carbonates 1	-S1
3.	Experimental procedures and characterization of compounds 3-5	-S4
4.	X-ray crystal structure of compound 3ag	-S26
5.	References	S27
6.	NMR spectra for compounds	S28

1. General information

Unless otherwise noted, materials were purchased from commercial suppliers and used without further purification. Column chromatography was performed on silica gel (200~300 mesh). Enantiomeric excesses (*ee*) were determined by HPLC using corresponding commercial chiral columns as stated at 30 °C with UV detector at 254 nm. Optical rotations were reported as follows: $[\alpha]_{D}^{T}$ (c g/100 mL, solvent). All ¹H NMR and ¹⁹F NMR spectra were recorded on a Bruker Avance II 400 MHz, ¹³C NMR spectra were recorded on a Bruker Avance III 101 MHz or Bruker Avance III 151 MHz with chemical shifts reported as ppm (in CDCl₃, TMS as an internal standard). Data for ¹H NMR are recorded as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, dd = double doublet, coupling constants in Hz, integration). HRMS (ESI) was obtained with a HRMS/MS instrument (LTQ Orbitrap XL TM). The absolute configuration of **3ag** was assigned by the X-ray analysis. Alkynyl ketones¹, pyrazole-4,5-diones² and catalysts **C6-C8**³ were synthesized according to the literature procedures.





A mixture of pyrazole-4,5-dione (5 mmol, 1.0 equiv.) and DABCO (1 mmol, 0.5 equiv.) in CH_2Cl_2 (3 mL) was stirred for 5 min at room temperature. Then methyl acrylate (15 mmol, 3.0 equiv.) was added dropwise into the solution and the reaction was monitored by TLC. After completion, the solvent was removed and the crude product was purified by column chromatography with *n*-hexane/ethyl acetate (3/1, v/v) to give adduct intermediate **b**.

To a solution of MBH adduct **b** (4.0 mmol, 1.0 equiv.) in CH_2Cl_2 (5 mL) was added to a stirred suspension of sodium hydride (6.0 mmol, 1.5 equiv.) in CH_2Cl_2 (10 mL) at 0 °C. After 0.5 h, a solution of (Boc)₂O (4.8 mmol, 1.2 equiv.) in CH_2Cl_2 (4 mL) was added slowly to the above mixture. The resulting solution was stirred at room temperature for 0.5 h - 4.0 hours. The reaction mixture was washed by saturated sodium bicarbonate solution (30 mL), extracted with CH_2Cl_2 (50 mL) and dried over Na₂SO₄. The solvent was removed and the crude product was directly purified by flash column chromatography with *n*-hexane/ethyl acetate (5/1, v/v) to afford the MBH carbonates **1a-1l**.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1a); The product was obtained as a white solid (72% yield for two steps); mp 146.6-147.3 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.00 (d, *J* = 8.1 Hz, 2H), 7.86 (dd, *J* = 6.2, 3.6 Hz, 2H), 7.53 – 7.36 (m, 5H), 7.23

(m, 1H), 6.73 (s, 2H), 3.60 (s, 3H), 1.35 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 168.1, 163.4, 138.1, 134.6, 130.7, 130.6, 129.4, 128.9, 128.8, 126.4, 125.4, 119.2, 84.9, 52.4, 27.5; HRMS (ESI) m/z Calcd. for C₂₄H₂₄N₂O₆+Na⁺ ([M+Na]⁺) 459.1527, Found 459.1517.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-1-(tert-butyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1b); The product was obtained as a white solid (67% yield for two steps); mp 107.9-108.6 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.80 – 7.66 (m, 2H), 7.41 – 7.29 (m, 3H), 6.59 (d, J = 9.8 Hz, 2H), 3.62 (s, 3H), 1.61 (s, 9H), 1.37 (s, 9H); ¹³C NMR (101 MHz, Chloroform-d) δ 169.1, 163.5, 149.7, 149.2, 134.9, 130.2, 129.8, 129.6, 128.6, 125.8, 84.0, 81.3, 58.3, 52.0, 27.9, 27.5; HRMS (ESI) m/z Calcd. for C₂₂H₂₉N₂O₆+H⁺ ([M+H]⁺) 417.2020, Found 417.12021.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-3-(4-fluorophenyl)-5-oxo-1phenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1c); The product was obtained as a white solid (76% yield for two steps); mp 141.5-142.4 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.98 (d, J = 8.2 Hz, 2H), 7.87 (m, 2H), 7.50 – 7.41 (m, 2H), 7.22 (d, J = 7.6 Hz, 1H), 7.09 (m, 2H), 6.72 (s, 2H), 3.61 (s, 3H), 1.35 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 163.3, 150.5, 149.5, 138.0, 134.5,

130.7, 128.9, 128.5, 128.4, 125.5, 119.3, 116.2, 116.0, 85.1, 52.5, 27.5; ^{19}F NMR (470 MHz, CDCl₃) δ -108.35 - -108.58; HRMS (ESI) m/z Calcd. for $C_{24}H_{23}FN_2O_6+Na^+([M+Na]^+)$ 477.1432, Found 477.1438.



Methyl 2-(3-(4-bromophenyl)-4-((tert-butoxycarbonyl)oxy) -5-oxo-1phenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1d); The product was obtained as a white solid (80% yield for two steps); mp 148.3-149.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.09 – 7.95 (m, 2H), 7.95 – 7.80 (m, 2H), 7.50 – 7.36 (m, 2H), 7.25 – 7.20 (m, 1H), 7.14 – 7.04 (m, 2H), 6.73 (d, J = 1.6 Hz, 2H), 3.61 (s, 3H), 1.36 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 167.9, 163.3,

150.5, 149.5, 138.0, 134.5, 130.7, 128.9, 128.5, 128.4, 125.5, 119.3, 116.2, 116.0, 85.1, 81.0, 52.5, 27.5; HRMS (ESI) m/z Calcd. for C₂₄H₂₃BrN₂O₆+Na⁺([M+Na]⁺) 539.0612, Found 539.0596.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-5-oxo-1-phenyl-3-(p-tolyl)-4,5dihy-dro-1H-pyrazol-4-yl)acrylate(1e); The product was obtained as a white solid (73% yield for two steps); mp 119.1-120.3 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.07 – 7.96 (m, 2H), 7.77 (d, J = 8.2 Hz, 2H), 7.44 (dd, J = 8.6, 7.3 Hz, 2H), 7.24 – 7.15 (m, 3H), 6.72 (d, J = 3.4 Hz, 2H), 3.59 (s, 3H), 2.38 (s, 3H), 1.35 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 151.6, 149.6, 141.0,

138.2, 134.7, 130.5, 129.6, 128.9, 126.6, 126.3, 125.3, 119.2, 84.9, 52.4, 27.5, 21.6; HRMS (ESI) m/z Calcd. for $C_{25}H_{26}N_2O_6+Na^+([M+Na]^+)$ 473.1683, Found 473.1692.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-3-(4-methoxyphenyl)-5-oxo-1phe- nyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1f); The product was obtained as a white solid (68% yield for two steps); mp 143.3-144.0 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.12 – 7.96 (m, 2H), 7.91 – 7.78 (m, 2H), 7.53 – 7.38 (m, 2H), 7.21 (m, *J* = 7.4 Hz, 1H), 7.02 – 6.87 (m, 2H), 6.70 (d, *J* = 1.7 Hz, 2H), 3.84 (s, 3H), 3.60 (s, 3H), 1.35 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*)

δ 163.4, 161.5, 138.2, 134.8, 130.3, 128.9, 128.1, 125.3, 122.0, 119.2, 114.3, 84.8, 55.3, 52.4, 27.5; HRMS (ESI) m/z Calcd. for C₂₅H₂₆N₂O₇+Na⁺([M+Na]⁺) 489.1632, Found 489.1641.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-5-oxo-1-phenyl-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1g); The product was obtained as a white solid (58% yield for two steps); mp 133.8-134.6 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.04 – 7.91 (m, 2H), 7.49 – 7.37 (m, 4H), 7.25 – 7.16 (m, 1H), 7.05 (dd, J = 5.1, 3.7 Hz, 1H), 6.73 (d, J = 3.0 Hz, 2H), 3.63 (s, 3H), 1.36 (s, 9H);

¹³C NMR (101 MHz, Chloroform-*d*) δ 163.3, 149.5, 138.0, 134.5, 132.4, 130.8, 128.9, 128.9, 128.4, 127.7, 125.5, 119.3, 85.0, 52.5, 27.5; HRMS (ESI) m/z Calcd. for $C_{22}H_{22}N_2O_6+Na^+([M+Na]^+)$ 465.1091, Found 465.1098.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-3-(naphthalen-1-yl)-5-oxo-1phenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1h); The product was obtained as a white solid (77% yield for two steps); mp 165.6-166.7 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 9.12 (d, *J* = 8.6 Hz, 1H), 8.20 – 8.00 (m, 2H), 7.89 (dd, *J* = 14.7, 8.1 Hz, 2H), 7.68 (d, *J* = 7.4 Hz, 1H), 7.61 (m, *J* = 7.7 Hz, 1H), 7.57 – 7.40 (m, 4H), 7.28 – 7.24 (m, 1H), 6.65 (d, *J* = 14.1 Hz, 2H), 3.60 (s, 3H),

1.34 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 151.7, 149.8, 138.2, 134.5, 134.3, 131.3, 130.8, 129.0, 128.6, 127.7, 127.0, 126.7, 126.4, 125.9, 125.5, 124.7, 119.3, 85.0, 82.3, 52.5, 27.5; HRMS (ESI) m/z Calcd. for C₂₈H₂₆N₂O₆+Na⁺([M+Na]⁺) 509.1683, Found 509.1690.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-3-(naphthalen-2-yl)-5-oxo-1phenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1i); The product was obtained as a white solid (82% yield for two steps); mp 168.4-169.8 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.22 – 8.11 (m, 2H), 8.05 (d, J = 8.0 Hz, 2H), 7.86 (dd, J = 12.1, 8.4 Hz, 2H), 7.60 – 7.42 (m, 4H), 7.24 (d, J = 7.2 Hz, 2H), 6.83 (d, 2H), 3.58 (s, 3H), 1.33 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 168.2, 163.4,

151.4, 138.1, 134.8, 132.9, 130.6, 129.0, 128.9, 128.8, 127.9, 127.5, 126.9, 126.7, 125.5, 123.1, 119.3, 85.0, 52.4, 27.5; HRMS (ESI) m/z Calcd. for $C_{28}H_{26}N_2O_6+Na^+([M+Na]^+)$ 509.1683, Found 509.1693.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-3-ethyl-5-oxo-1-phenyl-4,5dihydro-1H-pyrazol-4-yl)acrylate (1j); The product was obtained as a white solid (62% yield for two steps); mp 124.7-125.9 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.90 (d, *J* = 8.1 Hz, 2H), 7.40 (m, *J* = 7.8 Hz, 2H), 7.18 (m, *J* = 7.4 Hz, 1H), 6.60 (d, *J* = 59.6 Hz, 2H), 3.67 (s, 3H), 2.37 (m, *J* = 8.9 Hz, 2H),

1.44 (s, 9H), 1.23 (t, J = 7.5 Hz, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 168.2, 157.4, 138.1, 133.4, 131.0, 128.8, 125.1, 119.0, 84.7, 81.8, 52.5, 27.6, 21.1, 9.8; HRMS (ESI) m/z Calcd. for $C_{20}H_{24}N_2O_6+Na^+([M+Na]^+)$ 411.1527, Found 411.1536.



Methyl 2-(4-((tert-butoxycarbonyl)oxy)-3-cyclopropyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1k); The product was obtained as a white solid (62% yield for two steps); mp 144.6-145.8 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 – 7.78 (m, 2H), 7.45 – 7.33 (m, 2H), 7.21 – 7.09 (m, 1H), 6.62 (d, *J* = 53.7 Hz, 2H), 3.68 (s, 3H), 1.59 – 1.50 (m, 1H), 1.45 (s, 9H), 1.19 (m,

1H), 1.00 - 0.80 (m, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 163.5, 158.1, 149.7, 138.2, 133.4, 130.9, 128.8, 125.0, 118.9, 84.6, 81.7, 52.5, 27.6, 8.8, 8.3, 6.5; HRMS (ESI) m/z Calcd. for $C_{21}H_{24}N_2O_6+Na^+([M+Na]^+)$ 423.1527, Found 423.1534.



Butyl 2-(4-((tert-butoxycarbonyl)oxy)-5-oxo-1,3-diphenyl-4,5dihydro-1H-pyrazol-4-yl)acrylate (1l); The product was obtained as a white solid (69% yield for two steps); mp 145.4-146.3 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.14 – 7.97 (m, 2H), 7.93 – 7.81 (m, 2H), 7.51 – 7.36 (m, 5H), 6.71 (d, J = 10.9 Hz, 2H), 3.99 (m, 2H), 1.41 (dd, J = 8.5, 6.6 Hz, 2H),

1.35 (s, 9H), 1.22 – 1.05 (m, 2H), 0.75 (t, J = 7.4 Hz, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 163.1,

151.5, 138.2, 134.9, 130.6, 130.5, 129.4, 128.9, 128.8, 126.4, 125.3, 119.0, 84.9, 65.6, 30.2, 27.5, 19.0, 13.5; HRMS (ESI) m/z Calcd. for C₂₇H₃₀N₂O₆+Na⁺([M+Na]⁺) 501.1996, Found 501.2006.



Benzyl 2-(4-((tert-butoxycarbonyl)oxy)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-yl)acrylate (1m); The product was obtained as a white solid (80% yield for two steps); mp 169.1-169.8 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 (d, J = 8.0 Hz, 2H), 7.88 – 7.77 (m, 2H), 7.49 – 7.34 (m, 5H), 7.26 – 7.18 (m, 4H), 7.12 (d, J = 7.7 Hz, 2H), 6.75 (dd, J = 12.7, 1.5 Hz, 2H), 5.12 – 4.87 (m,

2H), 1.35 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 168.0, 149.6, 138.1, 134.7, 134.5, 131.0, 130.6, 129.3, 128.8, 128.8, 128.5, 128.4, 128.3, 126.4, 125.3, 119.2, 84.9, 67.3, 27.5; HRMS (ESI) m/z Calcd. for C₃₀H₂₈N₂O₆+Na⁺([M+Na]⁺) 535.1840, Found 535.1847.

3. Experimental procedures and characterization of compounds 3



A tube was charged with pyrazolone-derived MBH carbonates **1** (0.2 mmol), alkynyl ketone **2** (0.3 mmol), **C8** (0.02 mmol) and toluene (1 mL). The reaction was monitored by TLC. The product was directly purified by column chromatography on silica gel (petroleum ether/EtOAc = 10:1) to give the product **3**.

Compound 3aa



Prepared according to the procedure within 6 h as white solid (77.9 mg, 87% yield); mp 138.8-139.6 °C; $[\alpha]_{D}^{17} = -72.14$ (c 0.70, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.06 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 8.1 Hz, 2H), 7.87 (d, J = 7.6 Hz, 2H), 7.60 (m, 1H), 7.57 – 7.51 (m, 2H), 7.47 (m, 4H), 7.37 (m, 3H), 7.29 (d, J = 7.4 Hz, 1H), 7.03 (d, J = 1.7 Hz, 1H), 3.70 (s, 3H); ¹³C NMR (101 MHz,

Chloroform-*d*) δ 189.8, 165.7, 161.7, 152.8, 147.7, 144.7, 144.6, 139.2, 138.0, 136.8, 133.5, 131.2, 130.7, 129.4, 129.1, 129.0, 128.8, 126.0, 125.5, 119.5, 73.2, 52.3; HRMS (ESI) m/z Calcd. for $C_{28}H_{21}N_2O_4$ ([M+H]⁺) 449.1496, Found 449.1490; Enantiomeric excess was determined to be 92% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 12.0 min, tminor = 9.5 min).





Compound 3ba



Prepared according to the procedure within 10 h as yellow solid (69.4 mg, 81% yield); mp 112.3-113.8 °C; $[\alpha]_D^{19}$ = -51.87 (c 0.52, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.00 (d, *J* = 1.7 Hz, 1H), 7.84 (m, 3H), 7.58 (m, 1H), 7.52 (d, *J* = 7.5 Hz, 1H), 7.46 (m, 2H), 7.41 – 7.39 (m, 1H), 7.31 (dd, *J* = 10.2, 6.8 Hz, 2H), 6.94 (d, *J* = 1.6 Hz, 1H), 3.70 (s, 3H), 1.64 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.9, 166.8, 161.8, 149.9, 147.2, 145.1, 144.3, 138.9, 138.3,

137.0, 136.5, 134.1, 133.2, 131.5, 130.3, 130.1, 129.3, 128.9, 128.7, 125.0, 59.5, 52.0, 28.4; HRMS (ESI) m/z Calcd. for $C_{26}H_{25}N_2O_4$ ([M+H]⁺) 429.1809, Found 429.1808; Enantiomeric excess was determined to be 88% (determined by HPLC using chiral AD-H column, hexane/2-propanol = 15/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 15.8 min, tminor = 12.8 min).



[min] [min] mAU *s [mAU 00] ---|-----|----|-----|----____ _ _ _ _ _ ----| 1 12.381 MM T 1.5114 2.16147e4 238.34602 50.6210 15.414 MM R 1.7352 2.10844e4 234.19023 49.3790 2



Compound 3ca



Prepared according to the procedure within 10 h as white solid (85.8 mg, 92% yield); mp 128.3-129.4 °C; $[\alpha]_{D}^{17} = -48.64$ (*c* 0.22, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.05 (d, J = 1.7 Hz, 1H), 8.00 – 7.94 (m, 2H), 7.91 – 7.82 (m, 2H), 7.60 (m, 1H), 7.56 – 7.42 (m, 6H), 7.29 (d, J = 7.4 Hz, 1H), 7.08 – 6.96 (m, 3H), 3.70 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.7, 165.7, 165.6, 163.2, 161.7, 151.8, 147.8, 144.7, 144.3, 139.1, 137.9, 136.6, 133.6, 129.4, 129.1,

128.8, 127.6, 127.5, 127.0, 126.1, 119.5, 116.4, 116.2, 73.1, 52.3; ¹⁹F NMR (470 MHz, CDCl₃) δ -107.65 - -107.68; HRMS (ESI) m/z Calcd. for C₂₈H₂₀FN₂O₄ ([M+H]⁺) 467.1402, Found 467.1389. Enantiomeric excess was determined to be 91% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 9/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 27.3 min, tminor = 38.5 min).



Compound 3da



Prepared according to the procedure within 10 h as white solid (83.1 mg, 79% yield); mp 149.1-150.0 °C; $[\alpha]_{D}^{17} = -28.57$ (*c* 0.07, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.05 (d, J = 1.7 Hz, 1H), 7.99 – 7.93 (m, 2H), 7.89 – 7.82 (m, 2H), 7.65 – 7.56 (m, 1H), 7.52 – 7.43 (m, 6H), 7.42 – 7.35 (m, 2H), 7.29 (d, J = 7.4 Hz, 1H), 7.01 (d, J = 1.7 Hz, 1H), 3.70 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.7, 165.6, 161.7, 151.8, 147.9, 144.8, 144.1, 139.0, 137.9,

136.6, 133.6, 132.4, 129.6, 129.4, 129.1, 128.8, 126.8, 126.2, 125.6, 119.6, 72.9, 52.4; HRMS (ESI) m/z Calcd. for $C_{28}H_{20}BrN_2O_4$ ([M+H]⁺) 527.0601, Found 527.0578; Enantiomeric excess was determined to be 92% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor =15.2 min, tminor = 12.4 min).



Compound 3ea



Prepared according to the procedure within 12 h as white solid (83.2 mg, 90% yield); mp 168.1-169.3 °C; $[\alpha]_{D}^{17} = -25.00$ (*c* 0.16, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.06 (s, 1H), 7.99 (d, *J* = 8.0 Hz, 2H), 7.86 (d, *J* = 7.6 Hz, 2H), 7.59 (m, 1H), 7.46 (m, 6H), 7.28 (s, 1H), 7.15 (d, *J* = 7.9 Hz, 2H), 7.03 (s, 1H), 3.69 (s, 3H), 2.35 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.8, 165.7, 161.8, 147.5, 144.9, 144.6, 141.7, 139.3, 138.0, 136.8, 133.5, 129.8, 129.4, 129.0,

128.8, 128.0, 125.9, 125.4, 119.5, 73.3, 52.3, 21.6; HRMS (ESI) m/z Calcd. for $C_{29}H_{23}N_2O_4$ ([M+H]⁺) 463.1652, Found 463.1638; Enantiomeric excess was determined to be 96% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 9/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 17.2 min, tminor = 19.6 min).





Compound 3fa



Prepared according to the procedure within 12 h as white solid (87.0 mg, 91% yield); mp 130.1-131.3 °C; $[\alpha]_{D}^{17} = -89.00$ (*c* 0.20, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.05 (d, *J* = 1.8 Hz, 1H), 7.99 (d, *J* = 8.0 Hz, 2H), 7.91 – 7.79 (m, 2H), 7.60 (m, 1H), 7.55 – 7.38 (m, 6H), 7.28 (s, 1H), 7.04 (d, *J* = 1.9 Hz, 1H), 6.91 – 6.77 (m, 2H), 3.81 (s, 3H), 3.69 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.9, 165.6, 161.9, 161.8, 152.4, 147.4, 145.0, 144.5, 139.3,

138.1, 136.7, 133.5, 129.4, 129.0, 128.8, 127.1, 125.9, 123.4, 119.5, 114.5, 73.3, 55.4, 52.3; HRMS (ESI) m/z Calcd. for $C_{29}H_{23}N_2O_5$ ([M+H]⁺) 479.1601, Found 479.1580; Enantiomeric excess was determined to be 90% (determined by HPLC using chiral OD-H column, hexane/2-propanol =4/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 19.0 min, tminor = 15.2 min).



Compound 3ga



Prepared according to the procedure within 12 h as white solid (79.0 mg, 87% yield); mp 130.3-131.1 °C; $[\alpha]_{D}^{17} = -31.52$ (*c* 0.33, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.03 (s, 1H), 7.95 (dd, *J* = 14.4, 8.0 Hz, 3H), 7.77 (d, *J* = 8.0 Hz, 2H), 7.62 – 7.32 (m, 7H), 7.29 (d, *J* = 7.6 Hz, 1H), 7.03 (s, 1H), 3.70 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 188.3, 165.3, 161.6, 152.4, 146.9, 145.6, 143.6, 140.0, 139.8, 137.8, 132.6, 131.4, 130.6, 129.8, 129.2, 129.1, 126.2, 125.4, 119.5,

117.7, 116.7, 73.4, 52.5; HRMS (ESI) m/z Calcd. for $C_{26}H_{19}N_2O_4S$ ([M+H]⁺) 455.1060, Found 455.1049; Enantiomeric excess was determined to be 95% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 95/5, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 49.0 min, tminor = 67.4 min).



Compound 3ha



Prepared according to the procedure within 18 h as white solid (75.7 mg, 76% yield); mp 172.3-173.6 °C; $[\alpha]_{D}^{17} = -76.83$ (*c* 0.31, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 9.18 (d, J = 8.6 Hz, 1H), 8.05 (d, J = 8.1 Hz, 1H), 7.99 (d, J = 1.7 Hz, 1H), 7.93 – 7.87 (m, 2H), 7.82 (d, J = 7.6 Hz, 2H), 7.67 (m, J = 7.7 Hz, 1H), 7.62 – 7.56 (m, 2H), 7.48 (m, 5H), 7.39 – 7.29 (m, 2H), 7.15 (d, J = 6.7 Hz, 2H), 3.68 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.8, 165.5, 153.7,

147.5, 144.8, 144.5, 138.9, 138.1, 136.8, 134.2, 133.5, 131.9, 130.6, 129.4, 129.2, 128.8, 128.0, 126.9, 126.5, 126.2, 126.1, 126.0, 124.9, 119.5, 52.3; HRMS (ESI) m/z Calcd. for $C_{32}H_{23}N_2O_4$ ([M+H]⁺) 499.1652, Found 499.1636; Enantiomeric excess was determined to be 80% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 20.8 min, tminor =12.9 min).



Compound 3ia



Prepared according to the procedure within 14 h as white solid (79.7 mg, 80% yield); mp 169.1-170.1 °C; $[\alpha]_{D}^{17} = -86.79$ (*c* 0.40, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.17 – 8.11 (m, 1H), 8.05 (d, *J* = 8.0 Hz, 2H), 7.99 – 7.94 (m, 1H), 7.91 (d, *J* = 7.7 Hz, 2H), 7.87 – 7.81 (m, 2H), 7.76 (d, *J* = 7.8 Hz, 1H), 7.71 (s, 1H), 7.60 (m, 1H), 7.50 (m, 6H), 7.30 (m, 1H), 7.12 (d, *J* = 1.7 Hz, 1H), 3.69 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.8, 161.8, 147.7, 144.8, 144.7, 139.6, 138.0, 136.7, 134.5, 133.5, 133.0, 129.4, 129.1, 128.9, 128.3, 127.8, 127.7,

126.9, 126.1, 125.6, 122.4, 119.6, 73.2, 52.3; HRMS (ESI) m/z Calcd. for $C_{32}H_{23}N_2O_4$ ([M+H]⁺) 499.1652, Found 499.1633; Enantiomeric excess was determined to be 75% (determined by HPLC using chiral AD-H column, hexane/2-propanol = 8/2, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 23.9 min, tminor = 33.1 min).





Compound 3ja



Prepared according to the procedure within 22 h as white solid (70.4 mg, 88% yield); mp 167.4-168.6 °C; $[\alpha]_{D}^{17} = -96.69$ (*c* 0.32, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 7.95 (d, *J* = 1.9 Hz, 1H), 7.89 (d, *J* = 8.1 Hz, 2H), 7.85 (d, *J* = 7.6 Hz, 2H), 7.62 (m, 1H), 7.50 (m, 2H), 7.42 (m, 2H), 7.23 (s, 1H), 6.83 (d, *J* = 1.9 Hz, 1H), 3.77 (s, 3H), 2.22 (p, *J* = 7.8 Hz, 2H), 1.17 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.6, 166.2, 161.8, 158.9, 148.1, 145.4, 142.6,

138.0, 136.7, 133.5, 129.3, 129.0, 128.8, 125.6, 119.3, 74.6, 52.3, 22.8, 10.5; HRMS (ESI) m/z Calcd. for $C_{24}H_{21}N_2O_4$ ([M+H]⁺) 401.1496, Found 401.1488. Enantiomeric excess was determined to be 86% (determined by HPLC using chiral AD-H column, hexane/2-propanol = 8/2, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 10.2 min, tminor = 14.5 min).



Compound 3ka



Prepared according to the procedure within 20 h as white solid (70.9 mg, 86% yield); mp 160.1-161.0 °C; $[\alpha]_{D}^{17} = -56.33(c \ 0.20, CH_2Cl_2)$; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.98 (d, J = 1.8 Hz, 1H), 7.92 – 7.79 (m, 4H), 7.69 – 7.58 (m, 1H), 7.50 (dd, J = 8.4, 7.1 Hz, 2H), 7.45 – 7.35 (m, 2H), 7.25 – 7.15 (m, 1H), 6.87 (d, J = 1.8 Hz, 1H), 3.77 (s, 3H), 1.22 (m, 1H), 1.13 – 1.05 (m, 1H), 0.98 (m, 1H), 0.88 (m, 2H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.7, 166.0, 161.8, 159.5,

148.1, 145.3, 142.6, 138.0, 136.7, 136.7, 133.5, 129.4, 128.9, 128.8, 125.5, 119.2, 74.8, 52.3, 9.6, 9.3, 8.0; HRMS (ESI) m/z Calcd. for $C_{25}H_{21}N_2O_4$ ([M+H]⁺) 413.1496, Found 413.1487; Enantiomeric excess was determined to be 90% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 8/2, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 13.5 min, tminor = 16.7 min).



Compound 3la



Prepared according to the procedure within 22 h as white solid (82.4 mg, 84% yield); mp 179.6-180.8 °C; $[\alpha]_{\rm D}^{17}$ = -106.43 (*c* 0.60, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.11 (d, *J* = 1.7 Hz, 1H), 8.02 (d, *J* = 8.1 Hz, 2H), 7.91 – 7.83 (m, 2H), 7.61 – 7.53 (m, 3H), 7.51 – 7.44 (m, 4H), 7.38 (m, 3H), 7.28 (d, *J* = 7.4 Hz, 1H), 7.03 (d, *J* = 1.7 Hz, 1H), 4.07 (m, 2H), 1.45 (m, 2H), 1.28 – 1.16 (m, 2H), 0.74 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 188.8 , 164.7,

160.3, 151.8, 146.6, 143.8, 143.4, 138.5, 137.0, 135.7, 132.4, 130.2, 129.7, 128.4, 128.0, 128.0, 127.7, 124.8, 124.4, 118.1, 72.1, 64.2, 29.4, 18.0, 12.4; HRMS (ESI) m/z Calcd. for $C_{31}H_{27}N_2O_4$ ([M+H]⁺) 491.1965, Found 491.1947; Enantiomeric excess was determined to be 94% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 8/2, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 11.2

min, tminor = 8.5 min).



Compound 3ma



Prepared according to the procedure within 8 h as white solid (90.1 mg, 86% yield); mp 176.8-178.0 °C; $[\alpha]_{D}^{17}$ = -99.56 (*c* 0.34, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.10 (s, 1H), 7.83 (d, *J* = 7.8 Hz, 4H), 7.56 (m, 1H), 7.42 (m, 7H), 7.31 (m, 2H), 7.23 – 7.08 (m, 6H), 6.99 (s, 1H), 5.05 (s, 2H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.7, 165.6, 161.0, 152.7, 147.6, 145.4, 144.6, 139.0, 137.9, 136.7, 134.8, 133.5, 131.2, 130.7, 129.4, 129.1, 129.0, 128.8, 128.5, 128.3,

128.1, 125.9, 1255, 119.4, 73.2, 67.1; HRMS (ESI) m/z Calcd. for $C_{34}H_{25}N_2O_4$ ([M+H]⁺) 525.1809, Found 525.1806; Enantiomeric excess was determined to be 86% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 8/2, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 18.5 min, tminor = 13.3 min).





Compound 3ab



Prepared according to the procedure within 10 h as white solid (85.7 mg, 92% yield); mp 130.2-131.2 °C; $[\alpha]_{D}^{17} = -76.30$ (*c* 0.06, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.16 – 7.88 (m, 3H), 7.67 – 7.50 (m, 4H), 7.49 – 7.31 (m, 6H), 7.22 – 6.90 (m, 3H), 3.68 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 186.9, 165.4, 161.7, 161.4, 158.9, 152.7, 148.5, 145.9, 145.9, 143.5, 139.0, 138.0,

134.3, 134.2, 131.2, 130.8, 130.7, 129.1, 129.0, 126.0, 125.5, 124.7, 124.7, 119.5, 116.8, 116.6, 73.1, 52.3; ¹⁹F NMR (470 MHz, CDCl₃) δ -110.73 - -110.80; HRMS (ESI) m/z Calcd. for C₂₈H₂₀FN₂O₄ ([M+H]⁺) 467.1402, Found 467.1391; Enantiomeric excess was determined to be 98% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 95/5, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 44.1 min, tminor = 31.1 min).



Compound 3ac



Prepared according to the procedure within 10 h as white solid (78.2 mg, 81% yield); mp 138.6-139.0 °C; $[\alpha]_{\rm D}^{17}$ = -81.25 (*c* 0.40, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.04 (d, *J* = 1.7 Hz, 1H), 7.94 (d, *J* = 8.1 Hz, 2H), 7.56 – 7.52 (m, 2H), 7.43 (m, 6H), 7.34 (m, 3H), 7.31 – 7.26 (m, 1H), 6.93 (d, *J* = 1.8 Hz, 1H), 3.69 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.3, 165.3,

161.7, 152.6, 148.3, 146.9, 143.0, 139.4, 137.9, 137.4, 132.1, 131.2, 130.4, 129.4, 129.0, 127.1, 126.0, 125.6, 119.5, 73.1, 52.3; HRMS (ESI) m/z Calcd. for $C_{29}H_{20}CIN_2O_4$ ([M+H]⁺) 483.1106, Found 483.1098; Enantiomeric excess was determined to be 80% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 36.9 min, tminor = 24.9 min).



1.9694 3649.34375

3.7696 3.15902e4

Compound 3ad

1 2



24.974 MM T

36.888 MM T

Prepared according to the procedure within 10 h as white solid (79.5 mg, 86% yield); mp 128.5-129.3 °C; $[\alpha]_{\rm D}^{17}$ = -38.67 (*c* 0.15, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.09 (d, *J* = 1.8 Hz, 1H), 7.97 (d, *J* = 8.1 Hz, 2H), 7.61 – 7.50 (m, 2H), 7.50 – 7.33 (m, 7H), 7.27 – 7.15 (m, 3H), 6.88 (d, *J* = 1.7 Hz, 1H), 3.70 (s, 3H), 2.43 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*)

10.3558

89.6442

δ 192.1, 165.6, 161.8, 152.6, 149.2, 146.1, 143.8, 139.2, 138.0, 137.5, 137.0, 131.6, 131.4, 131.2, 130.8, 129.1, 129.0, 128.9, 126.0, 125.6, 125.4, 119.5, 73.1, 52.3, 20.2; HRMS (ESI) m/z Calcd. for C₂₉H₂₃N₂O₄ ([M+H]⁺) 463.1652, Found 463.1645; Enantiomeric excess was determined to be 90% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 30/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 34.1 min, tminor = 46.0 min).

30.88442

139.66913



Compound 3ae



Prepared according to the procedure within 12 h as white solid (86.8 mg, 90% yield); mp 128.4-129.6 °C; $[\alpha]_{D}^{17} = -93.33$ (*c* 0.80, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.12 – 7.88 (m, 3H), 7.80 (s, 1H), 7.68 (d, *J* = 7.8 Hz, 1H), 7.61 – 7.27 (m, 9H), 7.23 (d, *J* = 7.3 Hz, 1H), 7.01 (d, *J* = 1.8 Hz, 1H), 3.66 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 188.4, 165.5, 161.6,

152.6, 147.3, 144.9, 144.1, 135.3, 133.4, 131.3, 130.7, 130.1, 129. 2, 129.1, 129.1, 127.6, 126.1, 125.4, 119.6, 73.3, 52.3; HRMS (ESI) m/z Calcd. for $C_{28}H_{20}ClN_2O_4$ ([M+H]⁺) 483.1106, Found 483.1097; Enantiomeric excess was determined to be 90% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 9/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 19.2 min, tminor = 25.5 min).





Compound 3af



Prepared according to the procedure within 10 h as white solid (78.0 mg, 81 % yield); mp 128.9-129.8 °C; $[\alpha]_{D}^{17}$ = -34.25 (*c* 0.80, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.07 – 7.92 (m, 3H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.53 (d, *J* = 7.4 Hz, 2H), 7.50 – 7.43 (m, 4H), 7.40 (d, *J* = 7.0 Hz, 1H), 7.35 (m, 2H), 7.30 (s, 1H), 7.02 (d, *J* = 1.7 Hz, 1H), 3.70 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 188.5, 165.6, 161.7, 152.7, 147.4, 144.5, 144.4, 140.1, 139.4, 138.0, 135.0, 131.3,

130.8, 130.7, 129.2, 129.1, 129.1, 126.1, 125.4, 119.6, 73.2, 52.3; HRMS (ESI) m/z Calcd. for $C_{28}H_{20}ClN_2O_4$ ([M+H]⁺) 483.1106, Found 483.1095; Enantiomeric excess was determined to be 90% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 9/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 19.2 min, tminor = 24.6 min).



Compound 3ag



Prepared according to the procedure within 16 h as white solid (95.7 mg, 91% yield); mp 140.1-141.6 °C; $[\alpha]_{D}^{17}$ = -96.00 (*c* 0.10, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.02 (d, *J* = 1.8 Hz, 1H), 8.01 – 7.94 (m, 2H), 7.77 – 7.70 (m, 2H), 7.65 – 7.58 (m, 2H), 7.55 – 7.44 (m, 4H), 7.43 – 7.31 (m, 3H), 7.28 (s, 1H), 7.01 (d, *J* = 1.7 Hz, 1H), 3.70 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 188.7, 165.6, 161.7, 152.6, 147.4, 144.6, 144.3, 139.4, 137.9, 135.4, 132.2, 131.2,

130.9, 130.7, 129.1, 129.1, 128.8, 126.1, 125.4, 119.6, 73.2, 52.3; HRMS (ESI) m/z Calcd. for $C_{28}H_{20}BrN_2O_4$ ([M+H]⁺) 527.0601, Found 527.0591; Enantiomeric excess was determined to be 90% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 30/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 60.0 min, tminor = 81.1 min).



Compound 3ah



Prepared according to the procedure within 10 h as white solid (84.2 mg, 89% yield); mp 126.8-127.8 °C; $[\alpha]_{D}^{17}$ = -36.79 (*c* 0.28, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.05 (s, 1H), 7.95 (d, *J* = 8.1 Hz, 2H), 7.86 (d, *J* = 7.7 Hz, 2H), 7.60 (m, 1H), 7.56 – 7.33 (m, 6H), 7.28 (s, 1H), 7.03 (s, 1H), 6.97 (d, *J* = 4.2 Hz, 2H), 3.72 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.7, 165.5, 161.7, 148.4, 147.7, 145.0, 144.3, 138.8, 137.8, 136.6, 133.6, 133.3, 129.4, 129.2, 129.1,

128.8, 128.0, 127.3, 126.1, 119.6, 73.1, 52.4; HRMS (ESI) m/z Calcd. for $C_{29}H_{20}N_3O_4$ ([M+H]⁺) 474.1448, Found 474.1441; Enantiomeric excess was determined to be 67% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 9/1, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 61.4 min, tminor = 79.3 min).



Compound 3ai



Prepared according to the procedure within 12 h as white solid (70.2 mg, 76% yield); mp 136.4-137.3 °C; $[\alpha]_{D}^{17} = -47.25$ (*c* 0.80, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.05 (d, *J* = 1.8 Hz, 1H), 8.03 – 7.95 (m, 2H), 7.83 – 7.74 (m, 2H), 7.57 – 7.51 (m, 2H), 7.47 (dd, *J* = 8.6, 7.4 Hz, 2H), 7.44 – 7.38 (m, 1H), 7.35 (dd, *J* = 8.2, 6.4 Hz, 2H), 7.31 – 7.27 (m, 2H), 7.01 (d, *J* = 1.8 Hz, 1H), 3.69 (s, 3H), 2.41 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.5, 165.9,

161.8, 152.8, 147.8, 145.0, 144.6, 144.1, 139.0, 138.0, 134.1, 131.2, 130.7, 129.6, 129.5, 129.1, 129.1, 126.0, 125.5, 119.5, 73.1, 52.3, 21.8; HRMS (ESI) m/z Calcd. for $C_{29}H_{23}N_2O_4$ ([M+H]⁺) 463.1652, Found 463.1641; Enantiomeric excess was determined to be 96% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 8/2, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 51.7 min, tminor = 36.1 min).





Compound 3aj



Prepared according to the procedure within 12 h as white solid (78.4 mg, 82 % yield); mp 138.1-139.7 °C; $[\alpha]_{D}^{17} = -53.67$ (*c* 0.30, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.05 (d, *J* = 1.8 Hz, 1H), 7.99 (d, *J* = 8.0 Hz, 2H), 7.91 – 7.79 (m, 2H), 7.60 (m, 1H), 7.55 – 7.38 (m, 6H), 7.28 (s, 1H), 7.04 (d, *J* = 1.9 Hz, 1H), 6.91 – 6.77 (m, 2H), 3.81 (s, 3H), 3.69 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.9, 165.6, 161.9, 161.8, 152.4, 147.4, 145.0, 144.5,

139.3, 138.1, 136.7, 133.5, 129.4, 129.0, 128.8, 127.1, 125.9, 123.4, 119.5, 114.5, 73.3, 55.4, 52.3; HRMS (ESI) m/z Calcd. for $C_{29}H_{23}N_2O_5$ ([M+H]⁺) 479.1601, Found 479.1590; Enantiomeric excess was determined to be 94% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 9/1, $\lambda = 254$ nm, 30 °C, 0.8 mL/min, tmajor = 38.8 min, tminor = 45.9 min).



Compound 3ak



Prepared according to the procedure within 10 h as white solid (89.6 mg, 90 % yield); mp 136.3-137.2 °C; $[\alpha]_D^{17} = -59.23$ (*c* 0.26, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.37 (s, 1H), 8.10 (s, 1H), 8.01 (d, *J* = 8.1 Hz, 2H), 7.94 (d, *J* = 3.8 Hz, 2H), 7.89 (m, 2H), 7.58 (m, 4H), 7.48 (m, 2H), 7.40 (dd, *J* = 14.5, 7.1 Hz, 3H), 7.30 (s, 1H), 7.09 (s, 1H), 3.71 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 189.8, 165.8, 161.8, 152.8, 147.9, 144.8, 144.3, 139.2,

138.1, 135.7, 134.1, 132.3, 131.5, 131.2, 130.8, 129.7, 129.1, 129.1, 128.9, 127.9, 127.1, 126.0, 125.5, 124.7, 119.6, 73.2, 52.3; HRMS (ESI) m/z Calcd. for $C_{32}H_{23}N_2O_4$ ([M+H]⁺) 499.1652, Found 499.1642; Enantiomeric excess was determined to be 91% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 16.9 min, tminor = 12.4 min).



Compound 3al



Prepared according to the procedure within 12 h as white solid (79.9 mg, 88% yield); mp 127.0-127.8 °C; $[\alpha]_{D}^{17}$ = -30.63 (*c* 0.16, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.10 – 7.90 (m, 3H), 7.76 (dd, *J* = 17.3, 4.3 Hz, 2H), 7.54 (d, *J* = 7.5 Hz, 2H), 7.47 (m, 2H), 7.34 (m, 4H), 7.20 (s, 1H), 7.14 (m, 1H), 3.69 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 180.9, 165.7, 161.7, 152.8, 147.8, 144.5, 142.9, 139.2, 138.0, 135.3, 134.5, 131.2, 130.7, 129.1, 128.5, 126.0, 125.5, 119.5,

73.0, 52.3; HRMS (ESI) m/z Calcd. for $C_{26}H_{19}N_2O_4S$ ([M+H]⁺) 455.1060, Found 455.1049; Enantiomeric excess was determined to be 90% (determined by HPLC using chiral AS-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 17.6 min, tminor = 27.3 min).



Compound 3am



Prepared according to the procedure within 48 h as yellow liquid (55.2 mg, 58 % yield); $[\alpha]_{D}^{17} = -26.59$ (*c* 0.15, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 7.95 (d, *J* = 7.9 Hz, 3H), 7.45 (dd, *J* = 7.8, 4.0 Hz, 4H), 7.39 (m, 1H), 7.33 (q, *J* = 4.0 Hz, 2H), 7.25 (d, *J* = 4.2 Hz, 3H), 7.18 (d, *J* = 10.6 Hz, 3H), 7.13 (s, 1H), 3.66 (t, *J* = 2.9 Hz, 3H), 3.13 (dq, *J* = 7.1, 3.7, 3.3 Hz, 2H), 3.09 – 2.94 (m, 2H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 194.5, 165.5, 161.7, 152.6,

148.6, 143.1, 143.0, 140.4, 139.1, 137.9, 131.2, 130.7, 129.0, 129.0, 128.6, 128.3, 126.3, 126.0, 125.4, 119.5, 73.0, 52.3, 41.3, 29.6; HRMS (ESI) m/z Calcd. for $C_{30}H_{25}N_2O_4$ ([M+H]⁺) 477.1809, Found 477.1794; Enantiomeric excess was determined to be 55% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 8/2, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 31.9 min, tminor = 27.8 min).





Gram-scale Synthesis of 3ag



A tube was charged_with MBH Carbonates **1a** (870 mg, 2.0 mmol, 1.0 equiv), alkynyl ketone **2g** (620 mg, 3.0 mmol, 1.5 equiv), **C8** (81 mg, 0.2 mmol, 0.1 equiv) and toluene (10 mL) at rt. The reaction was monitored by TLC. The product was purified by column chromatography on silica gel (petroleum ether/EtOAc = 10:1) directly to give the product **3ag** 926 mg as white solid (88% yield, 90% ee).

The procedure for the synthesis of compounds 4



To a Schlenk tube were added **3ag** (53 mg, 0.1 mmol, 1.0 equiv), PhB(OH)₂ (25 mg, 0.2 mmol, 2.0 equiv), Pd(PPh₃)₄ (12 mg, 0.01 mmol, 0.1 equiv), Cs₂CO₃ (104 mg, 0.3 mmol, 3.0 equiv) and toluene/H₂O (4 mL/1 mL). The reaction mixture was stirred at 90 °C for 6 h under a nitrogen atmosphere. The product was purified by column chromatography on silica gel (petroleum ether/EtOAc = 5:1) to give the product **4** as yellow solid (43.0 mg, 82 % yield); mp 156.1-157.8 °C; $[\alpha]_{D}^{17} = -64.87$ (*c* 0.50, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.04 – 7.88 (m, 3H), 7.77 (d, *J* = 7.9 Hz, 2H), 7.69 (t, *J* = 8.4 Hz, 4H), 7.50 (ddd, *J* = 25.0, 18.7, 11.5 Hz, 12H), 3.20 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 188.5, 165.4, 158.4, 149.4, 145.3, 140.9, 139.9, 137.5, 135.3, 130.5, 129.0, 128.8, 128.3, 128.2, 127.3, 127.2, 126.2, 122.6, 118.6, 117.4, 51.2; HRMS (ESI) m/z Calcd. for C₃₄H₂₅N₂O₄ ([M+H]⁺) 525.1809, Found 525.1802; Enantiomeric excess was determined to be 88% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 10.2 min, tminor = 8.2 min).



The procedure for the synthesis of compounds 5



To a solution of **3aa** (54.0 mg, 0.1 mmol, 1.0 equiv) in MeOH (2.0 mL) was added sodium borohydride (5.0 mg, 0.12 mmol, 1.2 equiv) and CeCl₃⁻⁷H₂O (45 mg, 0.12 mmol, 1.2 equiv) at 0 °C for 30 min. The product was purified by silica gel column chromatography (petroleum ether/EtOAc = 10:1) to give **5** as white solid (30.6 mg, 68 % yield, 7:1 dr); mp 162.7-164.0 °C; $[\alpha]_{D}^{17} = -74.63$ (*c* 0.70, CH₂Cl₂); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.00 (d, *J* = 8.0 Hz, 2H), 7.51 – 7.42 (m, 9H), 7.39 (d, *J* = 7.5 Hz, 2H), 7.31 (s, 1H), 7.25 (s, 1H), 6.57 (s, 1H), 5.72 (s, 1H), 4.13 (s, 1H), 3.65 (s, 1H), 3.61 (s, 3H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 167.5, 161.8, 154.0, 153.9, 145.9, 140.8, 139.0, 138.2, 132.2, 130.8, 129.0, 128.9, 128.7, 128.6, 126.9, 125.7, 125.6, 119.5, 72.3, 71.4, 52.0; HRMS (ESI) m/z Calcd. for C₂₈H₂₃N₂O₄ ([M+H]⁺) 451.1652, Found 451.1655; Enantiomeric excess was determined to be 86% (determined by HPLC using chiral OD-H column, hexane/2-propanol = 7/3, λ = 254 nm, 30 °C, 0.8 mL/min, tmajor = 16.6 min, tminor = 10.3 min).



4. X-ray crystal structure of compound 3ag



CCDC: 2189938

Identification code	3ag
Empirical formula	$C_{27}H_{19}BrN_{3}O_{4}$
Formula weight	529.36
Temperature/K	295.0
Crystal system	orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁
a/Å	9.5080(5)
b/Å	12.3736(6)
c/Å	20.7192(11)
α/°	90
β/°	90
γ/°	90
Volume/Å ³	2437.6(2)
Z	4
$\rho_{calc}g/cm^3$	1.442
μ/mm^{-1}	1.725
F(000)	1076.0
Crystal size/mm ³	$0.21\times0.2\times0.15$
Radiation	MoKα (λ = 0.71073)
2Θ range for data collection/°	3.932 to 54.964
Index ranges	$-12 \le h \le 12, -16 \le k \le 16, -26 \le l \le 26$
Reflections collected	47283
Independent reflections	5592 [$R_{int} = 0.0760, R_{sigma} = 0.0534$]
Data/restraints/parameters	5592/0/317
Goodness-of-fit on F ²	1.096
Final R indexes [I>= 2σ (I)]	$R_1 = 0.0581, wR_2 = 0.1227$
Final R indexes [all data]	$R_1 = 0.0963, wR_2 = 0.1405$
Largest diff. peak/hole / e Å $^{-3}$	0.35/-1.19
Flack parameter	0.044(5)
CCDC number	2189938

5. References

(1) (a) F. Shi, S. Luo, L. Gong, *Org. Lett.*, 2011, **13**, 4680–4683; (b) A. Bugarin and B. T. Connell, *Tetrahedron Lett.*, 2015, **56**, 3285-3287; (c) J. Rong, H. Li, R. Fu, W. Sun, T.-P. Loh and Y. Jiang, *ACS Catal.*, 2020, **10**, 3664-3669.

(2) (a) P. Chauhan, S. Mahajan, U. Kaya, A. Peuronen, K. Rissanen and D. Enders, *J. Org. Chem.*, 2017, **82**, 7050-7058; (b) U. Kaya, P. Chauhan, S. Mahajan, K. Deckers, A. Valkonen, K. Rissanen and D. Enders, *Angew. Chem.*, *Int. Ed.*, 2017, **56**, 15358-15362; (a) K. Kumar, B. Singh, S. Hore and R. P. Singh, *New J. Chem.*, 2021, **45**, 13747-13750.

(3) (a) A. R. Choudhury and S. Mukherjee, *Org. Biomol. Chem.*, 2012, **10**, 7313-7320; (b) Y. Nakamoto, F. Urabe, K. Takahashi, J. Ishihara and S. Hatakeyama, *Chem.-Eur. J.*, 2013, **19**, 12653-12656.

6. NMR spectra for compounds



















S 36











210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0







210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0



























10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210













210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -













